Buy Oxyprogesterone Capronate solution 12.5%, 1 ml, 10 pcs
  • Buy Oxyprogesterone Capronate solution 12.5%, 1 ml, 10 pcs

Hydroxyprogesterone Caproate

1621 Items
Dosage form
Brand & Manufacturer
Package Size
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Oxyprogesterone is an analogue of the hormone of the corpus luteum (progesterone). Chemically different from progesterone in that in position 17 contains a residue of caproic acid. Being an ester of hydroxyprogesterone, is slower progesterone is metabolized (has a longer effect). After a single intramuscular injection of the oil solution, its action lasts from 7 to 14 days. Biological properties similar to progesterone. By binding to receptors on the surface of target organ cells, it penetrates into the nucleus, where, by activating DNA, it stimulates RNA synthesis. It promotes the transition of the uterine mucosa from the proliferation phase caused by follicular hormone to the secretory one, and after fertilization creates the necessary conditions for the implantation and development of a fertilized egg. Reduces the excitability and contractility of the muscles of the uterus and fallopian tubes, stimulates the development of end elements of the mammary gland.


Quickly and almost completely absorbed after intramuscular administration.

Metabolized in the liver to form conjugates with glucuronic and sulfuric acids.

T1 / 2 is 5 min. Excreted by the kidneys - 50-60%, with bile - more than 10%. The number of metabolites excreted by the kidneys varies depending on the phase of the corpus luteum


Conditions associated with insufficiency of the corpus luteum: threatening and begun miscarriage (prevention and treatment), amenorrhea (primary and secondary), dysfunctional uterine bleeding.


1 ml of solution contains:

Active ingredient: hydroxyprogesterone capronate;

Excipients: medical benzyl benzoate - 300 μl, olive oil - up to 1 ml.

No customer reviews for the moment.

Write your review

Write your review

Hydroxyprogesterone Caproate

Dosage and Administration


For the purpose of prevention and treatment of threatened and begun miscarriage injected at 0.125-0.25 g (1-2 ml of a 12.5% ​​solution) once a week. Apply only in the first half of pregnancy.

With amenorrhea (primary, secondary) is prescribed immediately after discontinuation of the use of estrogen drugs of 0.25 g, once, or in 2 administrations.

For the treatment of dysfunctional uterine bleedingthe drug is less convenient than progesterone, because its effect comes slowly, but it can be used to normalize the cycle: 0.0625-0.125 g (0.5-1 ml of 12.5% ​​solution) on days 20-22 of the cycle.

Adverse reactions

From the nervous system: drowsiness, headache, depression, apathy, dysphoria.

From the digestive system: cholestatic hepatitis, nausea, vomiting, loss of appetite, calculous cholecystitis.

From the genitourinary system: decreased libido, reduced menstrual cycle, intermediate bleeding.

From the senses: visual impairment.

From the CCC: increased blood pressure, edema, thromboembolism (including the pulmonary artery and brain vessels), thrombophlebitis, retinal vein thrombosis.

On the part of the endocrine system: galactorrhea, alopecia, weight gain, increase, pain and exertion of the mammary glands; hirsutism. Allergic reactions.

Local reactions: soreness at the injection site.


Carefully: in diseases of the cardiovascular system, arterial hypertension, chronic renal failure, diabetes mellitus, bronchial asthma, epilepsy, migraine, depression; hyperlipoproteinemia.

Treatment is often combined with the appointment of estrogen drugs or carried out directly after estrogen therapy.

Drug interactions

Weakens the effect of drugs that stimulate the reduction of myometrium (oxytocin), anabolic steroids (nandrolone), pituitary gonadotropic hormones.

Enhances the action of diuretics, antihypertensive drugs, immunosuppressants, bromocriptine.

Reduces the effectiveness of anticoagulants.

The progestogenic activity of the drug is reduced by inductors of microsomal oxidation (barbiturates, hydantoins, riffshitsin, etc.).

Pregnancy and Lactation

The drug is not used during pregnancy. In the event of pregnancy on the background of the drug should immediately discontinue treatment; data on the need for abortion is not. The drug is contraindicated in the second half of pregnancy and during breastfeeding.

Special instructions

In case of precipitation of crystals or crystallization of the entire contents of the ampoule, the ampoule should be heated in a boiling water bath with shaking. If the crystals disappear and the solution becomes transparent, and when cooled to 36-38 ° C, the crystals will not fall out again, the solution is suitable for use.

The purpose of the drug should be made only by the attending physician, under his control after an accurate diagnosis.

When treating amenorrhea in children, verification of the diagnosis of amenorrhea is primarily necessary.

Treatment before puberty should be aimed at stimulating growth. After 15-17 years old, estrogen and gestagen replacement therapy can be performed, which causes cyclic uterine bleeding!

Influence on ability to steer vehicles, mechanisms

Care should be taken when driving and other potentially hazardous activities that require increased concentration and psychomotor reactions, as the drug can cause side effects that can affect these abilities.


Symptoms: depression of the central nervous system, drowsiness, tachycardia; high blood pressure, weakness, sweating.

Treatment: discontinuation of therapy until symptoms disappear, followed by the administration of lower doses. If necessary, carry out symptomatic treatment.

  • Active ingredient: Hydroxyprogesterone

Studies and clinical trials of Hydroxyprogesterone Caproate (Click to expand)

  1. Hydroxyprogesterone caproate therapy in advanced endometrial cancer
  2. Effects of 17-hydroxyprogesterone caproate (17-OHPC) administration to pregnant squirrel monkeys (Saimiri boliviensis boliviensis)
  3. Quantitation of hydroxyprogesterone caproate, medroxyprogesterone acetate, and progesterone by reversed-phase high-pressure liquid chromatography
  4. High-performance liquid chromatographic analysis of the by-products of the synthesis of ethynylestradiol, mestranol, 17α-hydroxyprogesterone caproate and 17α-hydroxy-6-dehydroprogesterone acetate
  5. Development and validation of a high-performance liquid chromatography–mass spectrometric assay for the determination of 17α-hydroxyprogesterone caproate (17-OHPC) in human plasma
  6. Detection of 17α-hydroxyprogesterone caproate in equine plasma by gas chromatography/tandem mass spectrometry
  7. Effects of prenatally administered 17α-hydroxyprogesterone caproate on Adolescent males
  8. Impairment of male reproduction in adult rats exposed to hydroxyprogesterone caproate in utero
  9. Gestational exposure to hydroxyprogesterone caproate suppresses reproductive potential in male rats
  10. Single dose 17 alpha-hydroxyprogesterone caproate in preterm labor: a randomized trial
  11. Simultaneous quantitation of 17α-hydroxyprogesterone caproate, 17α-hydroxyprogesterone and progesterone in human plasma using high-performance liquid chromatography–mass spectrometry (HPLC–MS/MS)
  12. Efficacy of 17α-hydroxyprogesterone caproate in prevention of preterm delivery
  13. Endocrine effects of 17 alpha-hydroxyprogesterone caproate during early pregnancy: a double-blind clinical trial
  14. AWHONN Speaks Out Using 17 Alpha-Hydroxyprogesterone Caproate (17P) to Prevent Pre-term Birth
  15. Treatment of Persistent Acne in Women with 17 Alpha Hydroxyprogesterone Caproate (Delalutin)
  16. Treatment of Persistent Acne in Women with 17 Alpha Hydroxyprogesterone Caproate (Delalutin)
  17. Multigeneration Reproductive Study of Hydroxyprogesterone Caproate (HPC) in the Rat: Laboratory Results and Clinical Significance
  18. Evaluation of the teratogenic potential of Delalutin (17α-hydroxyprogesterone caproate) in mice
  19. Embryotoxicity of sex steroidal hormones in nonhuman primates: II. Hydroxyprogesterone caproate, estradiol valerate
  20. Trends in Prematurity: What do Changes at an Urban Institution Suggest About the Public Health Impact of 17-Alpha Hydroxyprogesterone Caproate?
  21. Evidences for Antinociceptive Effect of 17-Alpha-Hydroxyprogesterone Caproate in Carpal Tunnel Syndrome
  22. Hydroxyprogesterone caproate increases tumor necrosis factor- production from lipopolysaccharide stimulated whole blood in vitro
  23. Gestational age at initiation of 17 alpha-hydroxyprogesterone caproate (17P) and rate of preterm births in singleton gestations with a history of preterm delivery

Customers who bought this product also bought:

8 other products in the same category: